IRCT20220408054450N1 IRCT 2022-09-11 Bahria University Medical & Dental College Comparing Dapagliflozin and Glimepiride in treating patients with type 2 Diabetes. To compare the safety and efficacy of Dapagliflozin and Glimepiride as add‐on to Metformin in patients with type 2 diabetes. 2019-10-15 anticipated 200 Complete https://irct.ir/trial/63169 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: All the subjects were randomly divided into two groups, i.e., 1 and 2. Simple randomization through generation of random numbers was performed on excel sheet after generation of a series of numbers for the total sample size, which were then shuffled and randomized into a sequence using excel, the randomized number list (sequence) was used to allocate subjects in either group (intervention group 1 & 2) sequentially, No allocation concealment was used. 4 Type 2 Diabetes Mellitus. Intervention 1: Intervention group 1: Glimepiride (4mg) once daily and Metformin (500mg) three times a day orally for 12 weeks. Intervention 2: Intervention group 2: Dapagliflozin (10mg) once daily and Metformin (500mg) three times a day orally for 12 weeks. Yes - There is a plan to make this available What will be shared: All collected deidentified patient data can be made available, IPD collected for all outcome measures. When: When the publication is accepted by the journal. To whom: to the publishing journal. Conditions: For analysis purposes with due credit and acknowledgement to the author of this original research. data set can be requested via email once the article is published. Where to obtain: By email request from the contact person: Dr. Kamran Yousuf (kmran2010@gmail.com) How to obtain: Email request Comments: